On Monday, C4 Therapeutics Inc (NASDAQ: CCCC) opened lower -8.57% from the last session, before settling in for the closing price of $1.75. Price fluctuations for CCCC have ranged from $1.74 to $8.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 19.86% over the last five years. Company’s average yearly earnings per share was noted -21.75% at the time writing. With a float of $56.73 million, this company’s outstanding shares have now reached $70.63 million.
The firm has a total of 110 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.78%, operating margin of -336.15%, and the pretax margin is -295.6%.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of C4 Therapeutics Inc is 20.14%, while institutional ownership is 83.20%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -21.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.62% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Check out the current performance indicators for C4 Therapeutics Inc (CCCC). In the past quarter, the stock posted a quick ratio of 5.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.66 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Analysing the last 5-days average volume posted by the [C4 Therapeutics Inc, CCCC], we can find that recorded value of 0.97 million was lower than the volume posted last year of 1.51 million. As of the previous 9 days, the stock’s Stochastic %D was 4.74%. Additionally, its Average True Range was 0.18.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 0.30%, which indicates a significant decrease from 2.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.98% in the past 14 days, which was higher than the 80.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.8156, while its 200-day Moving Average is $4.6814. Now, the first resistance to watch is $1.6917. This is followed by the second major resistance level at $1.7833. The third major resistance level sits at $1.8367. If the price goes on to break the first support level at $1.5467, it is likely to go to the next support level at $1.4933. Now, if the price goes above the second support level, the third support stands at $1.4017.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are currently 70,990K shares outstanding in the company with a market cap of 113.58 million. Presently, the company’s annual sales total 35,580 K according to its annual income of -105,320 K. Last quarter, the company’s sales amounted to 5,180 K and its income totaled -34,570 K.
